Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The "fistula tract internal opening" describes the starting point of an anal fistula on the inside of the anal canal. In anal fistula—a pathological tunnel between the anal canal and perianal skin—the tract has two key sites: the external opening (on skin) and the internal opening (usually at the dentate line or within the anal canal). Identifying the precise location of the internal opening is crucial in surgical management, since failure to treat this area leads to persistent or recurrent disease. The internal opening is typically at the site of infection/blockage of the anal gland which initiates the fistula. This is an anatomic feature, not a molecular or therapeutic drug target. Key points: - This is an anatomic site, not a molecular structure, protein, enzyme, receptor, or cell-surface marker. - "Fistula tract internal opening" is not used in drug development or pharmacology as a druggable target. - Not appropriate for structured molecular/biological target fields typical in drug discovery documentation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fistula tract internal opening.